Christopher Chiu - Concepedia

Author

Christopher Chiu

Janssen (United States)ORCID

Also Known As

C Chiu, C. Chiu, C. W. Chiu, Chris Chiu, Christopher Chiu, Christopher W. Chiu, Tineke Casneuf

Publications

9.6K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Janssen (Belgium)Vejle Sygehus Emory University Genmab (United States)

About

Christopher Chiu is an author at Janssen (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	2.4K
2	Cell Biology	3	3	1K
3	Engineering	1	1	18
4	Health Sciences	1	1	922
5	Natural Sciences	1	1	18

Christopher Chiu

Publications

9.1K

Citations

H-Index

Page 1

	Year	Citations
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi, New England Journal of Medicine	2016	1.4K
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo, New England Journal of Medicine	2017	949
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Thierry Façon, Shaji Kumar, Torben Plesner, New England Journal of Medicine	2019	947
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau, Michel Attal, Cyrille Hulin, The Lancet Hematological MalignancyRadiation OncologyMedicineImmunologyHematology	2019	922
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis Hiroaki Nozawa, Christopher Chiu, Douglas Hanahan Proceedings of the National Academy of Sciences ImmunologyBiological MicroenvironmentsPathologyImmunoeditingImmunotherapy	2006	911
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières, Journal of Clinical Oncology	2022	484
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Blood	2017	438
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Blood	2016	371
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Martin Hutchings, Rogier Mous, Michael Roost Clausen, The Lancet Subcutaneous EpcoritamabLymphoid NeoplasiaDose EscalationMedicineDermatology	2021	315
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Haematologica	2018	254

Page 1